Connect with us

Hi, what are you looking for?

Alive Business PlanAlive Business Plan

Investing

Here’s why the Celsius Holdings stock price is ripe for more gains

Celsius Holdings stock price has bounced back in the past few weeks. CELH share price has rebounded from a low of $21 in February this year, to the current $45, its highest level since August 24. It has jumped by over 115% from the lowest point this year.

Celsius Holdings stock price technical analysis

The daily chart shows that the CELH stock price has bounced back in the past few months as investors bought the dip. It has recently formed a golden cross pattern as the 50-day and 200-day Exponential Moving Averages (EMA) crossed each other. A golden cross is one of the most bullish patterns in technical analysis.

Celsius Holdings share price has jumped above the 23.6% Fibonacci Retracement level. It is approaching the 38.2% retracement point at $50. 

CELH stock recently moved above the crucial resistance at $40, where it formed a small double-top pattern. The Relative Strength Index (RSI) and the MACD indicators have continued rising, a sign that it is gaining momentum. 

Celsius has also formed an inverse head-and-shoulders pattern, a popular bullish reversal sign.

Therefore, technicals suggest that the Celsius stock price will continue rising as bulls target the next key resistance level at $60, the 50% Fibonacci Retracement level. 

A drop below the key support at $40 will invalidate the bullish CELH stock price forecast. 

CELH stock chart | Source: TradingView

Key catalysts for the CELH stock price

There are a few reasons why the Celsius stock price is in an uptrend. First, the company recently closed the purchase of Alani in a $1.8 billion deal. 

Alani manufactures premium energy drinks, supplements, and other nutrition products. It made over $605 million in 2024 and had an adjusted EBITDA of $88 million. 

Most of its revenue comes from premium energy drinks, while the others are in products like shakes, pre-workout, and snacks. Celsius hopes that Alani will help it reach more female clients, who make up most of its customers. 

Celsius Holdings and Alani Nu had a combined annual revenue of $1.96 billion in 2024 and a net income margin of 12%. The deal is expected to yield approximately $50 million in annualized synergies.

Traders anticipate that the deal will help bring Celsius back to growth. The most recent financial results showed that Celsius’ sales dropped by 7% in Q1 to $329 million. This was a big reversal for a company that was recording double-digit growth in the past few months. 

Most of the decline came from North America, where revenue dropped by 10% to $306 million. This slowdown was offset by the 41% surge in its international sales, which rose to $22.8 million. 

Celsius Holdings’s profits also plunged, with the net income falling by 43% to $44 million and the diluted EPS falling to 15 cents. 

Analysts anticipate that Celsius Holdings revenue will surge by 58% in the current quarter to $636 million because of Alani’s purchase. This growth will translate to an annual revenue of $2.18 billion and $2.66 billion next year. 

The post Here’s why the Celsius Holdings stock price is ripe for more gains appeared first on Invezz

Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!

    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    You May Also Like

    Stock

    (TheNewswire) As global demand for rare earth magnets accelerates—driven by electric vehicles, renewable energy systems, and high-performance computing—the need for secure, domestic sources of...

    Economy

    Bitcoin Rebounds to $83,404 on April 11, 2025 Amid Renewed Investor Confidence On April 11, 2025, Bitcoin (BTC-USD) demonstrated a significant rebound, opening at...

    Stock

    Radiopharm Theranostics (ASX:RAD, ‘Radiopharm’ or the ‘Company’), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need,...

    Editor's Pick

    The post 36Crypto: Crypto Journalism with Realtime News and Insightful Analysis appeared first on Coinpedia Fintech News In an era where digital finance continues...



    Disclaimer: alivebusinessplan.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 alivebusinessplan.com